These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18413218)

  • 1. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort.
    Jenkins AJ; Rothen M; Klein RL; Moller K; Eldridge L; Zheng D; Durazo-Arvizu R; McGee D; Lackland D; Thorpe SR; Garvey WT; Lyons TJ;
    J Diabetes Complications; 2008; 22(3):153-63. PubMed ID: 18413218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
    Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
    Diabetes Care; 1999 Jan; 22(1):99-111. PubMed ID: 10333910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.
    Cleary PA; Orchard TJ; Genuth S; Wong ND; Detrano R; Backlund JY; Zinman B; Jacobson A; Sun W; Lachin JM; Nathan DM;
    Diabetes; 2006 Dec; 55(12):3556-65. PubMed ID: 17130504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.
    Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
    Diabetes; 1999 Feb; 48(2):383-90. PubMed ID: 10334318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia.
    Jenkins AJ; Lyons TJ; Zheng D; Otvos JD; Lackland DT; McGee D; Garvey WT; Klein RL;
    Diabetes Care; 2003 Mar; 26(3):810-8. PubMed ID: 12610042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort.
    Kim C; Cleary PA; Cowie CC; Braffett BH; Dunn RL; Larkin ME; Gatcomb PM; Wessells HB; Nathan DM; Sarma AV;
    Diabetes Care; 2014; 37(3):701-8. PubMed ID: 24170751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study.
    Purnell JQ; Zinman B; Brunzell JD;
    Circulation; 2013 Jan; 127(2):180-7. PubMed ID: 23212717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort.
    Klein RL; Hunter SJ; Jenkins AJ; Zheng D; Semler AJ; Clore J; Garvey WT;
    Diabetes Care; 2003 May; 26(5):1439-48. PubMed ID: 12716802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.
    ; Gubitosi-Klug RA; Sun W; Cleary PA; Braffett BH; Aiello LP; Das A; Tamborlane W; Klein R
    JAMA Ophthalmol; 2016 Feb; 134(2):137-45. PubMed ID: 26584339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.
    Martin CL; Albers JW; Pop-Busui R;
    Diabetes Care; 2014; 37(1):31-8. PubMed ID: 24356595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
    Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
    JAMA; 2003 Oct; 290(16):2159-67. PubMed ID: 14570951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.
    Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
    JAMA; 2002 May; 287(19):2563-9. PubMed ID: 12020338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort.
    Klein RL; McHenry MB; Lok KH; Hunter SJ; Le NA; Jenkins AJ; Zheng D; Semler A; Page G; Brown WV; Lyons TJ; Garvey WT;
    J Diabetes Complications; 2005; 19(1):18-25. PubMed ID: 15642486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).
    White NH; Cleary PA; Dahms W; Goldstein D; Malone J; Tamborlane WV;
    J Pediatr; 2001 Dec; 139(6):804-12. PubMed ID: 11743505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications.
    Lopes-Virella MF; Carter RE; Gilbert GE; Klein RL; Jaffa M; Jenkins AJ; Lyons TJ; Garvey WT; Virella G;
    Diabetes Care; 2008 Oct; 31(10):2006-12. PubMed ID: 18628568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC.
    Genuth SM; Backlund JY; Bayless M; Bluemke DA; Cleary PA; Crandall J; Lachin JM; Lima JA; Miao C; Turkbey EB;
    Diabetes; 2013 Oct; 62(10):3561-9. PubMed ID: 23520132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification.
    Colhoun HM; Schalkwijk C; Rubens MB; Stehouwer CD
    Diabetes Care; 2002 Oct; 25(10):1813-7. PubMed ID: 12351483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort.
    Lyons TJ; Jenkins AJ; Zheng D; Lackland DT; McGee D; Garvey WT; Klein RL
    Invest Ophthalmol Vis Sci; 2004 Mar; 45(3):910-8. PubMed ID: 14985310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction.
    Januszewski AS; Sachithanandan N; Karschimkus C; O'Neal DN; Yeung CK; Alkatib N; Jenkins AJ
    Diabet Med; 2012 Jun; 29(6):726-33. PubMed ID: 22211881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Increase in C-reactive protein plasma levels during diabetes in infants and young adults].
    Coulon J; Willems D; Dorchy H
    Presse Med; 2005 Jan; 34(2 Pt 1):89-93. PubMed ID: 15687975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.